Published in J Natl Cancer Inst on March 02, 2005
Molecular Epidemiology of Lung Adenocarcinoma in Multi-ethnic Asian Phenotype | NCT01774526
Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma | NCT03071705
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol (2009) 15.23
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med (2005) 6.04
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer (2010) 5.82
American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol (2009) 4.95
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80
A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol (2014) 4.54
BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med (2007) 4.50
A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A (2008) 4.45
Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev (2006) 4.06
PIK3CA mutations and copy number gains in human lung cancers. Cancer Res (2008) 3.42
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer (2009) 3.37
Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci U S A (2011) 3.10
The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer (2010) 3.03
Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol (2013) 2.90
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A (2012) 2.89
A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn (2010) 2.86
Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One (2009) 2.79
Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med (2011) 2.77
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol (2012) 2.76
Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res (2008) 2.71
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med (2013) 2.66
ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res (2013) 2.65
EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell (2012) 2.59
Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res (2012) 2.52
MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res (2010) 2.48
EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther (2013) 2.43
Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res (2009) 2.35
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol (2008) 2.28
Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res (2008) 2.28
New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol (2013) 2.25
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer (2008) 2.19
Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci U S A (2006) 2.17
High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer (2008) 2.16
Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res (2010) 2.14
Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol (2013) 2.04
Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res (2009) 2.03
Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res (2008) 2.00
Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer (2007) 2.00
EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J Mol Diagn (2008) 1.99
Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS One (2009) 1.94
Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer (2007) 1.87
EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am J Clin Pathol (2010) 1.86
New molecularly targeted therapies for lung cancer. J Clin Invest (2007) 1.86
Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets (2012) 1.85
Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res (2010) 1.83
SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol (2007) 1.79
Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol (2009) 1.78
Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn (2007) 1.77
Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Clin Cancer Res (2012) 1.77
Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res (2006) 1.75
Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol (2008) 1.73
Molecular biology of lung cancer. J Thorac Dis (2013) 1.67
Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res (2011) 1.66
Personalized medicine in lung cancer: what we need to know. Nat Rev Clin Oncol (2011) 1.65
Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. J Cell Mol Med (2009) 1.62
HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res (2009) 1.61
Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res (2008) 1.60
Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res (2009) 1.60
Notch1 mutations are drivers of oral tumorigenesis. Cancer Prev Res (Phila) (2014) 1.58
Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med (2013) 1.56
Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. Ther Adv Med Oncol (2011) 1.55
Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? Br J Cancer (2007) 1.55
EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget (2010) 1.53
Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med (2007) 1.52
Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma. Cancer Discov (2015) 1.51
XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer. Nature (2016) 1.51
Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. Proc Natl Acad Sci U S A (2008) 1.51
EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. Clin Cancer Res (2011) 1.50
Epidermal growth factor receptor mutations in lung adenocarcinoma. Lab Invest (2013) 1.49
Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res (2009) 1.48
MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer (2009) 1.48
Molecular biology of lung cancer: clinical implications. Clin Chest Med (2011) 1.47
Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas. Cancer Prev Res (Phila) (2008) 1.44
Pathogenesis of lung cancer: 100 year report. Am J Respir Cell Mol Biol (2005) 1.44
Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. Mol Cell Proteomics (2008) 1.44
Lung cancer in never smokers: molecular profiles and therapeutic implications. Clin Cancer Res (2009) 1.44
Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol (2010) 1.42
Immune Responses to the Cancer Testis Antigen XAGE-1b in Non Small Cell Lung Cancer Caucasian Patients. PLoS One (2016) 1.41
Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. J Clin Oncol (2013) 1.40
Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol (2006) 1.40
Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Br J Cancer (2005) 1.39
The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med (2007) 1.37
Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol (2013) 1.36
Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung. Mod Pathol (2009) 1.34
Emerging ethnic differences in lung cancer therapy. Br J Cancer (2008) 1.34
Frequency of EGFR mutations in 907 lung adenocarcioma patients of Indian ethnicity. PLoS One (2013) 1.32
Treatment of advanced non small cell lung cancer. J Thorac Dis (2011) 1.32
Targeted therapies: how personal should we go? Nat Rev Clin Oncol (2011) 1.31
A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment. J Natl Cancer Inst (2009) 1.31
Lung cancer cell lines: Useless artifacts or invaluable tools for medical science? Lung Cancer (2010) 1.30
Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. FEBS Lett (2010) 1.30
Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung. J Thorac Oncol (2008) 1.30
Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. Br J Cancer (2006) 1.29
EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res (2015) 1.29
High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation. J Thorac Oncol (2012) 1.28
Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. J Thorac Oncol (2010) 1.27
Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing. BMC Cancer (2011) 1.27
Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. Exp Ther Med (2011) 1.26
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol (2009) 21.94
Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68
A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature (2009) 18.39
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2006) 9.91
BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55
Suppression of aging in mice by the hormone Klotho. Science (2005) 8.11
Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Integrative annotation of 21,037 human genes validated by full-length cDNA clones. PLoS Biol (2004) 7.17
Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res (2002) 7.11
Association between body-mass index and risk of death in more than 1 million Asians. N Engl J Med (2011) 6.89
Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst (2008) 6.79
Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res (2008) 6.47
Lung cancer in never smokers--a different disease. Nat Rev Cancer (2007) 6.41
The medaka draft genome and insights into vertebrate genome evolution. Nature (2007) 5.77
Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res (2004) 5.57
Genome sequence of the ultrasmall unicellular red alga Cyanidioschyzon merolae 10D. Nature (2004) 5.08
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest (2009) 5.07
DMY is a Y-specific DM-domain gene required for male development in the medaka fish. Nature (2002) 4.73
Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res (2006) 4.72
Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature (2007) 4.70
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet (2012) 4.70
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One (2009) 4.62
Integrating the predictiveness of a marker with its performance as a classifier. Am J Epidemiol (2007) 4.59
Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell (2011) 4.54
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Role of TBX1 in human del22q11.2 syndrome. Lancet (2003) 4.45
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res (2007) 4.45
Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell (2007) 4.31
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res (2005) 4.25
Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res (2005) 3.98
Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer (2006) 3.92
LRP: role in vascular wall integrity and protection from atherosclerosis. Science (2003) 3.89
Genomic alterations in cultured human embryonic stem cells. Nat Genet (2005) 3.89
Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell (2011) 3.88
Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res (2005) 3.79
Real-time endobronchial ultrasound-guided transbronchial needle aspiration of mediastinal and hilar lymph nodes. Chest (2004) 3.79
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell (2006) 3.73
MicroRNA-146a feedback inhibits RIG-I-dependent Type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2. J Immunol (2009) 3.72
Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology (2005) 3.65
Identification of eight members of the Argonaute family in the human genome. Genomics (2003) 3.55
Evaluating the predictiveness of a continuous marker. Biometrics (2007) 3.54
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
Involvement of AGO1 and AGO2 in mammalian transcriptional silencing. Nat Struct Mol Biol (2006) 3.46
Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res (2006) 3.45
Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? Trends Mol Med (2004) 3.44
PIK3CA mutations and copy number gains in human lung cancers. Cancer Res (2008) 3.42
Focus on lung cancer. Cancer Cell (2002) 3.41
Genetic ablation of solute carrier family 7a3a leads to hepatic steatosis in zebrafish during fasting. Hepatology (2014) 3.40
Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res (2006) 3.40
LTRPC2 Ca2+-permeable channel activated by changes in redox status confers susceptibility to cell death. Mol Cell (2002) 3.36
Modulation of synaptic plasticity and memory by Reelin involves differential splicing of the lipoprotein receptor Apoer2. Neuron (2005) 3.25
Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res (2006) 3.21
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell (2006) 3.20
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res (2004) 3.20
A duplicated copy of DMRT1 in the sex-determining region of the Y chromosome of the medaka, Oryzias latipes. Proc Natl Acad Sci U S A (2002) 3.20
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol (2007) 3.19
Cross talk between microRNA and epigenetic regulation in adult neurogenesis. J Cell Biol (2010) 3.16
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res (2009) 3.13